pentobarbital de sodium effets PDF,Doc ,Images
Pentobarbital Sodium / Phenytoin Formulation - Merck
4 2 Principaux symptômes et effets aigus et différés Risques : Toxique en cas d'ingestion Peut provoquer une allergie cutanée Susceptible de provoquer le cancer en cas d'ingestion Susceptible de nuire à la fertilité ou au fœtus Risque avéré d'effets graves pour les organes
Pentobarbital Sodium / Phenytoin Formulation
9 avr. 2022 H351 Susceptible de provoquer le cancer en cas d'ingestion. H361 Susceptible de nuire à la fertilité ou au fœtus. H370 Risque avéré d'effets ...
Pentobarbital Sodium / Phenytoin Formulation - MSD
Pentobarbital Sodium / Phenytoin Formulation. Version. 7.3. Date de révision: 09.04.2022 H370: Risque avéré d'effets graves pour les or-.
Pentobarbital Sodium / Phenytoin Formulation - MSD
9 avr. 2022 H351 Susceptible de provoquer le cancer en cas d'ingestion. H361 Susceptible de nuire à la fertilité ou au fœtus. H370 Risque avéré d'effets ...
Intrarenal distribution of blood flow and renin release during renal
RVP effects a change in the intrarenal distribution of blood flow without affecting total RBF anesthetized with pentobarbital sodium (30 mg/kg) intra-.
RENSEIGNEMENTS DORDONNANCE INJECTION DE
26 févr. 2015 Injection de phénobarbital sodique USP ne doit pas être utilisé chez le nouveau-né. Pour éviter l'apparition d'effets secondaires et s'assurer ...
Influence of enzyme induction on the sleeping time of rats
I and 2) were due to the effect that phenobarbital and SKr" 525-A exerted on the enzyme systems con- trolling the metabolism of these anaesthetic agents.
Pentobarbital sodium
Appeler immédiatement un CENTRE ANTIPOISON/un médecin. Une surveillance médicale prolongée peut être indiquée. 4.2. Principaux symptômes et effets aigus et
RENSEIGNEMENTS ADDITIONNELS SUR LES EFFETS DES
La période précédant l'effet peut varier mais la mort survient dans les 30 et Rendig S.V. (1986) Sodium pentobarbital effects on cardiac function and ...
Remise de pentobarbital sodique lors dassistance au suicide
25 oct. 2017 Ordonnance du médecin (prescription magistrale). Mention: "dose létale" ou "pour assistance au suicide". Le produit doit être prescrit sous ...
Experiments with animals on the combined action of procaine and
Two principal effects of procaine on the central nervous system are known: hydrochloride sodium pentobarbital (Nembutal)
Uses of Pentobarbital
It is used to treat sleep problems.
What Do I Need to Tell My Doctor Before I Take Pentobarbital?
If you have an allergy to pentobarbitalor any other part of pentobarbital.
What Are Some Things I Need to Know Or Do While I Take Pentobarbital?
Tell all of your health care providers that you take pentobarbital. This includes your doctors, nurses, pharmacists, and dentists.
How Is This Medicine (Pentobarbital) Best taken?
Use pentobarbital as ordered by your doctor. Read all information given to you. Follow all instructions closely. 1. It is given as a shot into a muscle or vein. What do I do if I miss a dose? 1. Call your doctor to find out what to do.
What Are Some Side Effects That I Need to Call My Doctor About Right away?
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: For all uses of pentobarbital: 1. Signs of an allergic reaction, like rash;...
What Are Some Other Side Effects of Pentobarbital?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: 1. Feeling sleepy. These are not all of the side effects that may occur. If you have questions about side effects, call...
If Overdose Is Suspected
If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
How Do I Store and/or Throw Out Pentobarbital?
If you need to store pentobarbital at home, talk with your doctor, nurse, or pharmacist about how to store it.
Consumer Information Use and Disclaimer
If your symptoms or health problems do not get better or if they become worse, call your doctor.
What are the side effects of pentobarbital?
The main adverse reactions surrounding pentobarbital use are central nervous system effects, which include altered mental status, agitation, confusion, drowsiness, respiratory depression, bradycardia, hypotension, cardiovascular collapse, and syncope.
What is the use of sodium pentobarbital?
Sodium pentobarbital, a short-acting GABA A -receptor potentiator [ 11 ], is a reliable anesthetic for survival experiments, which is often used in urodynamic studies [ 4, 9, 12 – 28 ]. However, pentobarbital can abolish the micturition in some cases [ 12, 29, 30 ].
Is pentobarbital habit forming?
This medicine may be habit-forming with long-term use. Use pentobarbital for short periods of time. If signs show up again, talk with the doctor. If you have been taking pentobarbital on a regular basis and you stop it all of a sudden, you may have signs of withdrawal. Do not stop taking pentobarbital all of a sudden without calling your doctor.
How is pentobarbital toxicity treated?
[10] Treatment of pentobarbital toxicity involves supportive care, as there is no antidote. Overdose can lead to airway compromise, cardiovascular collapse, coma, and death. Treatment often requires intubation, hemodynamic support with vasopressors, and maintaining body temperature with warmers, commonly in an ICU setting.
[PDF] Pentobarbital Sodium / Phenytoin Formulation - Merck
23 mar 2020 · 1907/2006 Pentobarbital Sodium / Phenytoin Formulation Version 6 3 H370 Risque avéré d'effets graves pour les organes H373 Risque
Pentobarbital Sodium and Phenytoin Formulation AH BE FR
[PDF] NATRIUM PENTOBARBITAL 20 % - E-Compendium
1 ml de solution injectable contient : Pentobarbital sodique 200 mg – Propylène glycol – Éthanol - Alcool benzylique – Eau pour injection q s 4 INDICATIONS
NATRIUMPENTOBARBITAL PIL FR
Un cas darrêt cardiorespiratoire suite à une intoxication volontaire
volontaire par le pentobarbital actif est le pentobarbital sodique avec une concentration de probable participation d'une vasoplégie et de l'effet inotrope
ata
[PDF] Fiche de données de sécurité
16 oct 2019 · Nom du produit: Pentobarbital Sodium 57-33-0 Pentobarbital Sodium 4 2 Principaux symptômes et effets, aigus et différés Pas d'autres
(BE)
[PDF] Pentobarbital sodium - EDQM
Pentobarbital sodium Fiche de données de sécurité Fiche de sécurité conforme Règlement (CE) n° 1907/2006 (REACH) Date d'émission: 19/12/2019 Version:
EDQM . SDS FR
EchocardiographicAssessmentofCatsAnesthetizedwithXylazine-SodiumPentobarbitalD.G.AllenandR.S.Downey*ABSTRACTLeftventricularechocardio-graphicparametersincatswererecorded,measuredandanalyzedtostudytheeffectsofacombinationofxylazineandsodiumpentobarbitalonleftventricularfunction.Thedepressanteffectsofacombinationofxylazineandsodiumpentobarbitalontheleftventriculardimensionatenddiastole,thepercentchangeinminordiameterandthevelocityofcircumferentialfibreshort-eningwerecomparedtoecho-cardiographicvaluesofunanes-thetizedcats.Nochangeinheartratewasnoted.Strokevolumeandcardiacoutputweredepressed.RESUMf2CetteexperienceconsistaitAenregistrer,mesureretana-lyserlesparametresdel'echo-cardiographieduventriculegauche,chezdeschats,afind'6tudierleseffetsdel'anes-th6sieAlaxylazineetaupento-barbitalsodiquesurlafonctionduventriculegauche.Lesauteurscomparbrentleseffetsdeprimantsdel'utilisationsimultan6edesdeuxanesth&siquesprecit6ssurladimensionduventriculegauche,Alafindeladiastole,lepourcentagedechangementdesonpluspetitdiam!treetlav6locit6durac-courcissementdelacircon-ferencedesesfibres,aveclesvaleursde1'echocardiographiedechatsnonanesth6sies.Ilsneconstatbrentpasdechangementdelafrequencecardiaque,maisunedepressiondesdebitssysto-liqueetcardiaque.INTRODUCTIONEchocardiographyistheac-ceptedtermforthestudyofcar-diacultrasoundandhasonlyrecentlybeenusedintheclinicaldiagnosisandassessmentofcar-diacdiseaseinveterinarymedi-cine(12).Asaresearchtoolithasbeenusedtoassesstheeffectsofphysicalandchemicalagentsonventricularfunction(4,5).Ithasrecentlybeenusedtoassesstheeffectsofsodiumpentobarbitalonleftventricularfunctionincats(1).Theprinciples,theadvantagesandthedisadvantagesofechocar-diographyhavebeenoutlinedinpreviousreports(1,4,12,16).Itwasthepurposeofthisprojecttostudytheeffectsechocardiographicallyofaxylazine-sodiumpentobarbitalcombinationonleftventricularfunction.Echocardiographiceval-uationofcardiacfunctionoffersanoninvasiveadjuncttoothermodesofcardiacinvestigation.MATERIALSANDMETHODSHighresolutionrecordingsofM-modeechocardiogramsandsimul-taneouslyrecordedelectrocardio-gramswereobtainedoneachcat.'Afivemegahertz,sixmillimeternonfocusedtransducerwasused.Eightmaturecatsofanybreedandeithersexwereusedintheexperiment.Theywerejudgedashavinganormalcardiovascularsystempriortoechocardiographicstudyonthebasisofhistory,physi-calexamination,electrocardio-gramsandchestradiographs(1,13).Thecatswereanesthetizedwithanintravenousbolusofxyla-zine2(1.25mg/kg)(9,11)followedintenminuteswithanintravenousbolusofsodiumpentobarbital3(30mg/kg)(18,21).Theechocardiographicstudywascarriedoutwiththecatplacedinleftlateralrecumbencyaspre-viouslydescribed(1,14).Thestudywascompletedwhensatisfactoryrecordingsoftheleftventriclewereobtained.Methodsformeas-uringleftventricularparametersarereportedpreviously(4,5).Thevalueschosenrepresentthosemostoftenrecordedinanechocardiographicstudyofven-tricularfunction.Theyincludetheleftventriculardimensionatenddiastolewhichcorrelateswithpre-load(5),theleftventricularsys-tolicdimension,thepercentchangeinleftventricularminordiameter,thevelocityofcircum-ferentialfibreshortening,thelat-tertwoofwhichareindicesofcon-tractility(1,14,16),theejectiontimeandtheheartrate.Thecombinedxylazine-sodiumpentobarbitalanestheticregimen*DepartmentofClinicalStudies,OntarioVeterinaryCollege,UniversityofGuelph,Guelph,OntarioNlG2W1.SubmittedMay13,1982.'EchoIV,Echocardiograph/SimultraceRecorder,Pleasantville,NewYork.2Rompun,Haver-LockhartLaboratories,Shawnee,Kansas.3Somnotol,MTCPharmaceuticals,Hamilton,Ontario.CanJCompMed1983;47:281-283.281
TABLEI.EchocardiographicParametersofEightCatsAnestheiXylazine-SodiumPentobarbitalandSignificance"p"toTwenty-fiveUnaiCatsinaPreviousStudy(13)ParameterLeftVentricularDiastolicDimension(LVDd)-(cm)LeftVentricularSystolicDimension(LVDs)(cm)PercentChangeinMinorDiameter(%dD)EjectionTime(E.T.)(sec.)VelocityofCircumferentialFibreShortening(VcF)(cm/sec)HeartRate(beats/min)BodyWeight(kg)waschosenbecausebothdrugshavebeenusedaloneorincombi-nationinexperimentalphysiologyandpharmacologyandinclinicalpractice(7,11,20).Theechocardio-graphicassessmentofthisdrugcombinationhasnotbeenpre-viouslyreported.Theechocardiographicparame-tersobtainedinthisprojectwerestatisticallycomparedwiththoseofunanesthetizedcatsbyapre-viousinvestigator(13).The"pvalue"wasusedtodeterminewhichcomparisonvaluesweresignificant(TableI).Avalueof"p"lessthan0.05wasconsideredsig-nificantinthisstudy.ThemeanandstandarddeviationoftheechocardiographicparametersfromeachstudyarealsoshowninTableI.RESULTSTheeffectsofanesthetizingcatswithxylazine-sodiumpentobarbi-talonthevariousechocardiogra-phicmeasurementsareshowninTableI.Themeandimensionoftheleftventricleatenddiastole(LVDd)was1.29±0.09centimeters.Asignificantanestheticeffectwasdemonstratedwhenunanesthet-izedcatswerecomparedtocatsanesthetizedwithxylazine-sodiumpentobarbital.Themeandimensionoftheleftventricleinsystole(LVDs)was0.88±0.08centimeters.Themeanpercentchangeinminordiameter(0%dD)ofcatsanes-thetizedwithxylazine-pentobar-bitalwas31.11±4.67percentMeanStd.Dev."1.290.8831.110.162.02163.003.500.090.084.670.020.4513.000.41changeinleftventriculdiameter.Therewasasicombinedanestheticeff(%dD.Theejectiontime(E.]anesthetizedwithxylazibarbitalwas0.16±0.02TherewasnosignificEtheticeffectontheejecwhenunanesthetizedccomparedtocatsanEwithxylazine-sodiumbarbital.Themeanvalueofthevcircumferentialfibresi(VcF)oftheleftventi2.02±0.45centimetersTherewasasignificantthecombinedanestheti(VcF.ThemeanheartratEanesthetizedwithxylazibarbitalwas163+13bute.Thexylazine-sodiubarbitalcombinationsignificanteffectonheathisstudy.Themeanbodyweigianesthetizedwithxylazibarbitalwas3.5±0.41kDISCUSSIONEchocardiographypsafenoninvasiveassesscardiacfunction(4,5,1obtainedbythismethodIlatedwellwithdataobiotherinvasivetechniquefactthatdatacanbeobtainvasivelyfurtherreduiwhichmightbeintroduepresenceofarecordinsuchasanintracardiac(21).Cardiacperform;tizedwithbeenevaluatedbyassessingthenesthetizedleftventriculardiastolicdimen-sion(LVDd)whichhasbeencorre-'p"valuelatedwithpreload,cardiaccon-tractilitywhichhasbeencor-0.0relatedwiththevelocityofcircumferentialfibreshortening-(VcF)andthepercentchangeinminordiameter(%dD),theheart0.0001rateandafterload(5).0.113Preloadisdefinedastheleftven-0.002tricularwallstressatenddiastole.0.348Sincestress,bytheLaplaceLaw,istheresultofintracardiacpressure,dimensionandwallthickness,thelarminorLVDdcanbeusedtoassesspre-ignificantload(5).CardiaccontractilitymayectonthebeassessedbytheindicesofVcFandthe%dD(1,4,16).TheVcFisr.)ofcatsunaffectedbychangesinpreload,ine-pento-inverselyaffectedbyacutechanges!seconds.inafterloadanddirectlyaffectedantanes-byinotropicstimulation(6,9,17).tiontimeHeartrateisanotherindicatoratswereofcardiacperformanceandcon-?sthetizedtributestocardiacoutput.Cardiacpento-outputremainsoneofthemostoftenusefulindicesofcardiacper-relocityofformance(6,8).Afterloadwasnothorteningassessedinthisproject.ridlewasTheleftventricularsystolic3/second.dimension(LVDs)wasusedtocal-effectofculatethe%dDandtheVcF.TheesontheejectiontimewasusedtocalculatetheVcF(4,5).eincatsXylazinehasbeenusedaloneorine-pento-incombinationwithvariousanes-eats/min-theticregimens(7,9,10,15,19).mpento-Usedalone,xylazineisanadren-hadnoergic-cholinergicneuroninhibitorrtrateinproducingrapidinduction,goodtoexcellentsedationlastingoneoritofcatstwohours,excellentanalgesialast-ine-pento-ing15to30minutesandasmoothilograms.recovery(7,9,11,19).TheanalgesiaandsedationaretheresultofCNSdepressionandthemusclerelaxa-tionisduetotheinhibitionofintraneuraltransmissionofim-termitsapulsesintheCNS(7).Initiallysmentofafterintravenousorintramuscu-L7).Datalarinjectionxylazineproducesahascorre-shortelevationinarterialbloodtainedbypressureduetoitsalphastimula-,s(5).Thetoryeffectandanincreaseincon-tinednon-tractilityindependentoftheheartceserrorrate(8,9).Itisfollowedbyamoreedbytheprofounddecreaseinarterialigdevicebloodpressureduetoadecreaseincatheteraorticbloodflow.Thedecreasedancehasaorticflowisareflectionofthe282
sympatholyticeffectandthedecreaseinheartrate(9).Thereisalsoafallintherespiratoryrateandcardiacoutput(18).AlthoughtherespiratoryrateisdecreasedthetidalvolumeisincreasedsoastablearterialpHandbloodgastensionismaintained(9).Ahighincidenceofseconddegreeheartblockhasbeennotedinpreviousstudies(3,9,15).Seconddegreeheartblockwasrecordedinthreeofeightcatsafterintravenousxyl-azineadministrationinthisstudy.Asstatedinapreviousstudy(1),sodiumpentobarbitalhasminoreffectsoncardiacoutput,arterialbloodpressureandperipheralre-sistance.Fifteenminutesafteranintravenousinjectionof30mg/kg,thecardiacoutput,arterialpres-sureandperipheralresistancereturntorestingvalues(21).Itsvagolyticactioncausesanincreaseintheheartrate.Myocardialcon-tractilityorVcFandstrokevolumehoweverremaindepressed(6,21).ThedepressedVcFand%dDarearesultofincompleteven-tricularemptyingandnotadecreaseinenddiastolicsize(21).Athighdosesanegativechrono-tropiceffectwithsinoatrialandatrioventricularblockmaybeseen(14,20).Pentobarbitalremainsoneofthemostwidelyusedanestheticsinexperimentalpharmacologyandphysiology(20).Thecombinationofxylazineasapreanestheticandpentobarbitalforanesthesiawasstudiedclini-cally(7,11).Inaresponsefrompractitionerstheoverallperfor-manceofthedrugcombinationin87%ofcaseswasgoodtoexcellentafterintravenousinjection(11).Theuseofxylazinewithbarbitu-ratesdecreasesthedoseofbarbi-turaterequiredby75%ormoreafterintravenousinjectionandrecoveryissmooth(7).Theeffectofxylazine-sodiumpentobarbitalwastodepresstheleftventriculardiastolicdimen-sionwhichrelatestopreload,andthepercentchangeinminordiameterandthevelocityofcir-cumferentialfibreshorteningastheseindicesrelatetomyocardialcontractility.Theseeffectswerealsonotedinapreviousstudyofsodiumpentobarbitalusedalone(1).Nosignificantchangeinheartrateorejectiontimewasdemon-stratedinthepresentstudy.Adecreaseinpreloadwithoutachangeincontractilitycausesadecreaseincardiacoutput(5).SincetheheartrateremainedunchangedandsincepreloadasindicatedbytheLVDdandthecontractilityasrelatedtoVcFand%dDweredecreased,cardiacout-putcanbeexpectedtobedecreasedwithsodiumpentobar-bitalincombinationwithxylazine.Cardiacoutputisaproductofthestrokevolumeandtheheartrate,wherestrokevolumeisdependentuponafterload,preloadandcon-tractility.Thexylazine-sodiumpentobarbitalcombinationcausedadecreaseincontractilityorthe%dDandVcFaswellasthepre-loadorLVDdbuthadnoeffectontheheartrate.Thereforestrokevolumeandcardiacoutputisexpectedtofall.Nosignificantchangeinheartratewasdemon-stratedincatsanesthetizedwithaxylazine-pentobarbitalcombina-tion.Theeffectsanestheticshaveonheartratearelargelyduetotheireffectsontheautonomicner-voussystem(6).Theparasympa-tholyticactionofpentobarbitalandtheparasympathomimeticactionofxylazinemayhaveactedsuchthatoneeffectnegatedtheotherandnosignificanteffectonheartrateresulted.Ejectiontimeisdirectlyaffectedbychangesinheartrateandsincenochangeinheartrateoccurredwiththedrugcombinationnochangeinejectiontimewasexpected.REFERENCES1.ALLEN,D.G.Echocardiographicstudyoftheanesthetizedcat.Can.J.comp.Med.46:115-122.1982.2.BAKER,M.L.andG.V.DALRYM-PLE.Biologicaleffectsofdiagnosticultrasound.Radiology126:479-483.1978.3.COHEN,R.B.andL.P.TILLEY.Cardiacarrhythmiasintheanesthet-izedpatient.Vet.Clin.North.Am.9:155-167.1979.4.FIEGENBAUM,H.Echocardio-graphy,2ndEdition.pp.1-328.Phila-delphia:Lea&Febiger.1976.5.HIROTA,Y.,M.SUWA,K.HORIandT.TAKATSU.Dynamicechoven-triculography.Noninvasiveassessmentofeffectsofnitroglycerin,phenyle-phrine,isoproterenolandpropanololonthehumancardiovascularsystem.Jap.HeartJ.19:719-731.1978.6.MERIN,R.G.Effectofanestheticsontheheart.Surg.Clin.North.Am.55:759-774.1975.7.MOYE,R.J.,A.PAILETandM.W.SMITH.Clinicaluseofxylazineindogsandcats.Vet.Med.smallAnim.Clin.68:236-241.1973.8.MUIR,W.N.Anesthesiaandtheheart.J.Am.vet.med.Ass.171:92-97.1977.9.MUIR,W.andF.S.PIPER.Effectofxylazineonindicesofmyocardialcon-tractilityinthedog.Am.J.vet.Res.38:931-934.1977.10.MUIR,W.,R.T.SKARDAandD.W.MILNE.Evaluationofxylazineandketaminehydrochlorideforanesthesiainhorses.Am.J.vetRes.38:195-201.1977.11.NEWKIRK,H.L.andD.G.MILES.Xylazineasasedative-analgesicfordogsandcats.Mod.Vet.Pract.55:677-680.1974.12.PIPERS,F.S.andR.L.HAMLIN.Clinicaluseofechocardiographyinthedomesticcat.J.Am.vet.med.Ass.176:57-61.1980.13.PIPERS,F.S.,V.REEFandR.L.HAMLIN.Echocardiographyinthedomesticcat.Am.J.vet.Res.40:882-886.1979.14.PRATILA,M.G.andV.PRATILAS.Anestheticagentsandcardiacelectro-mechanicalactivity.Anesthesiology49:338-360.1978.15.PUROHIT,R.C.,P.W.MYSINGERandR.W.REDDING.Effectsofxyla-zineandketaminehydrochlorideinthehorse.Am.J.vet.Res.42:615.1981.16.QUINONES,M.A.,W.H.GAASHandJ.K.ALEXANDER.Echocardio-graphicassessmentofleftventricularfunction.Circulation50:42-51.1974.17.QUINONES,M.A.,W.H.GAASCHandJ.K.ALEXANDER.Influenceofacutechangesinpreload,afterload,contractilestate,andheartrateonejec-tionandisovolumicindicesofmyocar-dialcontractility.Circulation53:293-302.1976.18.SOMA,L.R.TextbookofVeterinaryAnesthesia.pp.265,324.Baltimore:WilliamsandWilkins.1971.19.STEPHENSON,J.C.,D.L.BLE-VINSandG.J.CHRISTIE.SafetyofRompun/Ketasetcombinationindogs.Vet.Med.smallAnim.Clin.73:303-305.1978.20.URTHALER,F.,B.L.KRAMESandT.N.JAMES.Selectiveeffectsofpen-tobarbitalonautomaticityandconduc-tionintheintactcanineheart.Cardio-vascularResearch8:46-57.1974.21.VATNER,S.F.andE.BRAUN-WALD.Cardiovascularcontrolmech-anismsintheconsciousstate.NewEngl.J.Med.6:970-976.1975.283
